Stocks Health care KMTS
NASDAQ · Health careKestra Medical Technologies, Ltd. (KMTS)
Kestra Medical Technologies, Ltd. brought in $106.7M of revenue over the twelve months to July 31, 2026, up 60.7% from a year earlier. It posted a net loss of $149.9M. In fiscal 2026 capital spending exceeded operating cash flow by $116.6M. At July 31, 2026 it held $68.6M in cash against $72.5M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 14, 2026.
Key facts about Kestra Medical Technologies, Ltd.
- Net worth
- Kestra Medical Technologies, Ltd. has a market value (market cap) of $1.8B at the latest share price, and shareholders' equity of $222.4M on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2026 revenue was $95.1M (+59.0% year on year), with a net loss of $131.6M. Over the 12 months to July 31, 2026: revenue $106.7M, net loss $149.9M.
- Cash flow
- In fiscal 2026 operations used $81.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on September 14, 2026 and covers the period to July 31, 2026. Open on SEC EDGAR
- Next earnings report
- Kestra Medical Technologies, Ltd.'s next report is expected around November 30, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Kestra Medical Technologies, Ltd. does
Kestra Medical Technologies, Ltd. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker KMTS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $95.1M | -$131.6M | -$2.43 | -$116.6M |
| 2025 | $59.8M | -$113.8M | -$5.13 | -$100.5M |
| 2025 | $27.8M | -$94.1M | -$5.07 | -$84.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where KMTS ranks in Health care
Latest SEC filings
What Kestra Medical Technologies, Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026Quarterly report10-Q · period to July 31, 2026Kestra Medical Technologies reported higher revenue alongside an increased net loss for the quarter ended July 31, 2026.Revenue rose 60% to $31M versus the same quarter last year; diluted EPS -$0.75 versus -$0.50.
- September 14, 2026Quarterly results8-KKestra Medical Technologies reported a 60% revenue increase for the first quarter of fiscal 2027 and raised its full-year revenue guidance.
- September 10, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- July 28, 2026
- July 28, 2026Additional proxy material DEFA14A
- July 28, 2026Proxy statement DEF 14A
- July 14, 2026Annual report 10-K · period to April 30, 2026Revenue rose 59% to $95.1M versus the prior year; diluted EPS -$2.43 versus -$5.13.
- July 14, 2026
- April 8, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Kestra Medical Technologies, Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $7.6M worth of shares in the last 90 days and bought none on the open market. Most of the selling (91%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Moran Timothy P.Chief Business Officer | Sold | 3,192 | $94.4K |
| October 29, 2026 | Mahboob VaseemChief Financial Officer | Exercised options | 4,788 | $81.4K |
| October 29, 2026 | Mahboob VaseemChief Financial Officer | Soldpre-planned (10b5-1) | 4,788 | $146.5K |
| October 28, 2026 | Mahboob VaseemChief Financial Officer | Exercised options | 39,903 | $678.4K |
| October 28, 2026 | Mahboob VaseemChief Financial Officer | Soldpre-planned (10b5-1) | 39,903 | $1.2M |
| October 27, 2026 | Umberger Traci SSee Remarks, Director | Exercised options | 30,000 | $510K |
| October 27, 2026 | Umberger Traci SSee Remarks, Director | Soldpre-planned (10b5-1) | 30,000 | $900.9K |
| October 27, 2026 | Mahboob VaseemChief Financial Officer | Exercised options | 34,809 | $591.8K |
Who owns KMTS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bain Charger Holdings, L.P.13G, passive | 43.1% | February 17, 2026 |
| Fmr LLC13G, passive with 1 related filers | 10.2% | October 7, 2025 |
| T. Rowe Price Associates, Inc.13G, passive | 8.5% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 109 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Bain Capital Investors LLC | 25,172,338 | 0 |
| Fmr LLC | 5,523,647 | -197,407 |
| Andera Partners | 2,728,679 | +33,487 |
| Yu Fan | 2,282,519 | 0 |
| Brown Advisory Inc | 1,909,056 | +185,326 |
| BlackRock, Inc. | 1,865,496 | +176,249 |
| Eventide Asset Management, LLC | 1,446,742 | +878 |
| Vanguard Capital Management LLC | 1,175,525 | -37,168 |
| Alliancebernstein L.P. | 1,477,992 | +157,618 |
| Franklin Resources Inc | 1,123,622 | -119,583 |
| Omega Fund Management, LLC | 1,022,149 | 0 |
| Hood River Capital Management LLC | 753,529 | +97,652 |
| State Street Corp | 747,703 | +76,591 |
| Geode Capital Management, LLC | 647,380 | +73,455 |
| Point72 Asset Management, L.P. | 526,626 | new |
| Federated Hermes, Inc. | 525,000 | 0 |
| Next Century Growth Investors LLC | 458,505 | +947 |
| Driehaus Capital Management LLC | 448,608 | +1,293 |
| UBS Group AG | 325,838 | -23,849 |
| Goldman Sachs Group Inc | 304,384 | +16,030 |
Insiders
11 insiders reported holding 1,223,596 shares in total, about $36.9M at the last price.
| Holder | Shares |
|---|---|
| Webster Brian DanielSee Remarks, Director | 445,215 |
| Umberger Traci SSee Remarks, Director | 358,627 |
| Moran Timothy P.Chief Business Officer | 105,641 |
| Ford Alfred J JrChief Commercial Officer | 99,564 |
| Mahboob VaseemChief Financial Officer | 60,609 |
| Cohen Raymond WDirector | 54,790 |
| Ladone Mary KayDirector | 44,724 |
| Schwartz Jeffrey LawrenceDirector, 10% owner | 14,236 |
| Kwo ElizabethDirector | 14,116 |
| Hanley ConorDirector | 13,489 |
Questions about KMTS
What does Kestra Medical Technologies, Ltd. do?
Kestra Medical Technologies, Ltd. is a company in the Health care sector, listed on NASDAQ as KMTS. Its shares trade on NASDAQ under the ticker KMTS.
What is Kestra Medical Technologies, Ltd.'s net worth?
Kestra Medical Technologies, Ltd. has a market value (market cap) of $1.8B at the latest share price, and shareholders' equity of $222.4M on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Kestra Medical Technologies, Ltd. profitable?
No. Over the twelve months to July 31, 2026 it reported a net loss of $149.9M on revenue of $106.7M.
How much revenue does Kestra Medical Technologies, Ltd. make?
Over the twelve months to July 31, 2026 Kestra Medical Technologies, Ltd. reported revenue of $106.7M. That is 60.7% more than a year earlier.
When did Kestra Medical Technologies, Ltd. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on September 14, 2026. It covers the period to July 31, 2026. Its newest filing of any kind is the insider trade from November 5, 2026.
When is Kestra Medical Technologies, Ltd.'s next earnings report?
Kestra Medical Technologies, Ltd.'s next report is expected around November 30, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare KMTS with
Follow KMTS
Get an email when Kestra Medical Technologies, Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Kestra Medical Technologies, Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.